Alto Neuroscience (ANRO) Stock Forecast: StockMap's 2-Week Call
ANRO stock forecast: StockMap's model makes no two-week call on Alto Neuroscience after the Nov 19 close: its evidence is split, 6 reasons for and 9 against. Right in 2 of 3 two-week windows on ANRO since Sep 9; by chance, a call on the same dates was right 59% of the time.
Alto Neuroscience last closed at $26.51, +2.32% on the session.
Against the IVW growth benchmark the position is +4.65% over the forecast window.
Alto Neuroscience's market cap is $1.06B as of November 19, 2026.
No call today: the model sees no clear direction · the next 2 weeks, vs S&P 500 growth. The lean on a scale from −100 to +100 is -10 (too close to call).
Where ANRO sits: sized by market cap, coloured by the day's move.
The read is built from 15 underlying insights — 6 bullish and 9 bearish.
Agreement across those insights is 60%.
13 daily calls for ANRO so far. We publish our accuracy across thousands of stocks in the open, misses included — no per-stock hit rate is claimed on a small sample.
On the fundamentals StockMap ranks Alto Neuroscience in the 19th percentile on return on equity, where 100 is best.
Alto Neuroscience is classified under Health Care / Pharmaceuticals.
StockMap tracks Alto Neuroscience as the 62nd largest of the 153 companies it covers in the Pharmaceuticals industry, part of the Health Care sector.
Across that group the current two-week reads are 80 Moderate Underperform, 44 Neutral and 29 Strong Underperform.
On that composite Alto Neuroscience ranks 26th of 153 in the group, against a group median of -0.36.